# A Global Prospective Observational Registry of Patients With Pompe Disease

> **NCT06121011** · — · RECRUITING · sponsor: **Amicus Therapeutics** · enrollment: 500 (estimated)

## Conditions studied

- Pompe Disease

## Interventions

- **BIOLOGICAL:** Cipaglucosidase alfa
- **DRUG:** Miglustat
- **BIOLOGICAL:** Alglucosidase alfa or Avalglucosidase alfa
- **OTHER:** Untreated

## Key facts

- **NCT ID:** NCT06121011
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-16
- **Primary completion:** 2034-12-20
- **Final completion:** 2034-12-20
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121011, "A Global Prospective Observational Registry of Patients With Pompe Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06121011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*